Company: INDP
Filing Date: 2025-07-01
Form Type: 8-K
Source: 0001641172-25-017283
Chunk: 1

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-07-01
Form: 8-K
Item: Item 1.01
Chunk 1
---
 such holder of the Notes would beneficially own in excess of 4.99% or 9.99% of
the shares of Common Stock outstanding immediately after giving effect to such conversion, then in lieu of receipt of shares of Common
Stock upon conversion, the holder shall receive such pre-funded warrants, in substantially the same form as the Warrants, but with an
exercise price for the pre-funded warrants of $0.01 per share and no expiration date (the “ Pre-Funded Warrants”).

Within
10 days of the later of the Conversion Date and the date stockholder approval is obtained, each Purchaser will receive a Warrant exercisable
for shares of the Company’s Common Stock in a number equal to 200% of the Conversion Shares. The Warrants are exercisable on the date which is the later of (i) the Conversion Date and (ii) the
date stockholder approval is obtained and will expire on the five year anniversary thereafter. The Warrants will have an exercise price
equal to the Conversion Price. Pursuant to the Purchase Agreements, the Company has agreed to file
a registration statement within 30 days of the Conversion Date providing for the resale of the Conversion Shares and shares of Common
Stock underlying the Warrants (the “ Warrant Shares”). The Company has also agreed to use commercially reasonable efforts
to cause such registration statement to become effective within 60 days following the Conversion Date and to use commercially reasonable
efforts to keep such registration statement effective at all times until the earlier of (i) the date that no Purchaser owns any Conversion
Shares, Warrants or Warrant Shares issuable upon exercise thereof and (ii) the two year anniversary of the closing date.

In
compliance with Nasdaq Listing Rule 5635(d), the Company and the Purchasers agreed that the Company will not issue Conversion
Shares if it would exceed the aggregate number of shares of Common Stock which the Company may issue upon conversion of the Convertible
Notes without breaching the Company’s obligations under Nasdaq Listing Rule 5635(d). Pursuant to the Purchase Agreement, the Company
agreed to hold a special stockholder meeting in order to seek stockholder approval which is currently scheduled to be held on July
25, 2025.

The
foregoing descriptions of the Purchase Agreement, Notes and Warrants are qualified by reference to the full text of such documents, a
form of each of which are filed as Exhibits 10.1, 10.2